| Status: Medicine does not meet criteria for AWMSG assessment | |
Excluded from appraisal by AWMSG as meets exclusion criteria 15. See AWMSG criteria for appraising a medicine (PDF, 430Kb) for information. |
|
Medicine details |
|
| Medicine name | nonacog beta pegol (Refixia®) |
| Formulation | 500 IU, 1,000 IU and 2,000 IU powder and solvent for solution for injection |
| Reference number | 3828 |
| Indication | Treatment and prophylaxis of bleeding in patients 12 years and above with haemophilia B (congenital factor IX deficiency) |
| Company | Novo Nordisk Ltd |
| BNF chapter | Cardiovascular system |
| Submission type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 03/09/2018 |